← All trials
NCT06373731
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 30, 2024
- Primary completion
- Aug 31, 2026
- Completion date
- Aug 31, 2027
- First posted
- Apr 18, 2024
- Last posted
- Nov 5, 2024
- Enrollment
- 360
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Stealth BioTherapeutics Inc.Lead sponsor
- Stealth BioTherapeutics Inc.Official
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.